TxCell has exercised its exclusive option to in-license the intellectual property rights of one of its academic partners, the University of British Columbia (UBC), onto its HLA-A2 CAR-Treg programme. Read more


A Master Service Agreement has been entered by TxCell and Lonza Pharma & Biotech for the manufacture of a CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation. Read more


A biotechnology company, TxCell, Inserm Transfert and Nantes University have signed a R&D collaboration agreement for the development of chimeric antigen receptor (CAR) engineered CD8+Treg cells (CAR-Tregs). Read more


TxCell, a biotechnology company developing personalised cell-based immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, will participate at the second French Life Sciences Days. Read more